

# **Determining Potency of Immunologic Therapy:**

## **Assessing Dendritic Cell Vaccines**

**Karolina Palucka, MD, PhD**

**Baylor Institute for Immunology Research, Center for Human Vaccines, Dallas  
Mount Sinai School of Medicine, Dept of Cell and Gene Therapy, New York**


# **Assessing Dendritic Cell Vaccines:**

**Ten years of experience with  
ex vivo generated DC vaccines**

---

- **cGMP Vaccine manufacture core**
- **cGMP Cell and Tissue Procurement Core**
- **GLP Immunomonitoring Core including  
polychromatic flow and genomics**

# Baylor closed system for DC vaccines



*Roberts, Burkeholder, Taquet, Walters, Finholt*


# **Assessing Dendritic Cell Vaccines:**

**Ten years of experience with  
ex vivo generated DC vaccines**

---

- **Immune and clinical outcomes**
- **Assessing potency of vaccine products**
- **Predictive biomarkers of vaccine efficacy**

# Distinct DC subsets induce distinct type of immune responses





Banchereau & Palucka, 2005

Nature Reviews | Immunology

# DENDRITIC CELL MATURATIONS

The control point of cellular immunity

---



**Microbial Products:**

TLR, NOD and lectin ligands  
LPS, DNA, RNA

**Tissue damage:**

Uric acid, HSPs

**Cells of innate  
immunity**

pDC, NK, NK T,  
Neutrophils  
IFN, TNF, GM-CSF

**Cells of adaptive  
immunity**


T and B cells  
CD40 L, RANK

Immature DC




Mature DC

# BIIR DENDRITIC CELL VACCINE TRIALS: FIRST GENERATION TRIALS IN METASTATIC MELANOMA




# Peptide & KLH -pulsed CD34-DCs

Progressive patients do not mount TAA-specific responses




Boosting vaccinations can maintain long-lived melanoma-specific memory T cells




*Palucka et al. J Immunother 2003*  
*Palucka et al J Immunotherapy 2005*

# DC vaccine loaded with killed allogeneic melanoma cells can induce durable clinical responses (2+1/20 patients)




# DC vaccine loaded with killed allogeneic melanoma cells can induce durable clinical responses (2+1/20 patients)





*Palucka et al. J Immunotherapy 2006*

# Clinical Responders and Long term survivors: the key to design of efficient therapeutic cancer vaccine




# DC vaccines can expand long-lived melanoma-antigen specific CD8<sup>+</sup> memory T cells




*Ueno, Palucka*

# DC vaccines can expand high avidity polyfunctional MART-1 melanoma-antigen specific CD8<sup>+</sup> T cells




# EPIMAX: Assessment of Antigen-specific T cell repertoire ex vivo



*Ueno*


# Patients with metastatic melanoma have circulating melanoma antigen-specific IL10-producing T cells at baseline




Vence et al PNAS 2007

# Patients with Metastatic Melanoma Display Circulating Tumor Antigen-specific T regs


Determination of IL-10-inducing peptide



Proliferation of peptide-specific T regs




Suppressive function of specific T regs



Vence et al. PNAS, 2007


# Breast cancer tumors are infiltrated by CD4<sup>+</sup> T cells secreting IL-13




# Breast cancer cells show IL-13 staining and display an IL-13 signature (pSTAT6)

---

IL-13



pSTAT6



*Aspord et al. J.Exp.Med. 2007 Vol.204: 1037*

# **Assessing Dendritic Cell Vaccines:**

---

- **Immune and clinical outcomes to define biomarkers of efficacy:**
  - **Which patient populations to assess immunogenicity:**  
**MRD vs metastatic disease**

.....

# Assessing Dendritic Cell Vaccines: Multivariate analysis

---

Cells	Antigens	Activators	Route of injection
CD34-DCs GM/IL4-DCs GM/IFN-DCs GM/IL15-DCs Alpha DC1 pDCs	Peptides Vectors Killed cells Nucleic acids Proteins .....	Cytokines CD40 L Gal Cer TLR ligands .....	SC ID IV IN IL .....

**Mechanism/Infrastructure  
for analysis from many trials  
to draw statistically meaningful conclusions**

# Thanks to our patients

SUPPORT: BUMC FOUNDATION, SAMMONS CANCER CENTER,  
NCI, NIAID, INSERM, ANRS,

Dr M. Ramsay

- Vaccine:
    - S. Burkeholder
    - M. Leogier
    - F. Kerneis
    - M. Michnevitz
    - J. Finholt-Perry
  - Cell and Tissue Core:
    - L. Walters
  - cGMP Lab:
    - L. Roberts
    - N. Taquet
  - Targeting
    - G. Zurawski
    - S. Zurawski
    - AL. Flamar
    - E. Klechevsky
    - SK. Oh
- Clinical Core:
    - Joe Fay
    - S. Hicks
    - B-J. Chang
    - D. Wood
  - Post-docs/Students:
    - C. Aspord
    - F. Berard
    - P. Blanco
    - P. Dubsky
    - D. Frleta
    - E. Klechevsky
    - A. Pedroza
    - S. Paczesny
    - H. Saito
    - L. Vence
    - C. Yu
  - Immunomonitoring:
    - Hide Ueno
    - J-P. Blanck
    - L. Boudery
    - J. Shay
  - Microarrays
    - D. Chaussabel
    - N. Baldwin
  - R. Steinman
  - M. Dhodapkar
  - Y. Reiter
  - F. Marches
  - M. Gallegos
  - S. Tindle
  - M. Michnevitz

JACQUES BANCHEREAU

AND MANY  
BIIR MEMBERS.....